Pharmaceuticals

Global Chimeric Antibody Market Size Projected to Reach $21.31 Billion During the Forecast Period

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Chimeric Antibody Industry Compare Between 2025 And 2029?

The market size for chimeric antibodies has experienced swift expansion in recent years. It is anticipated to expand from $12.27 billion in 2024 to $13.74 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.0%. The expansion observed in the past can be attributed to several factors, including increasing cancer incidence rates, a rising demand for immunotherapy, growing investment in biologics, the increasing adoption of monoclonal antibodies, and an elevated prevalence of autoimmune diseases.

The chimeric antibody market is projected to experience substantial expansion over the forthcoming years. This market is anticipated to reach $21.31 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.6%. Key factors driving this growth during the forecast period include an escalating emphasis on targeted therapies, heightened clinical trial activities, expanding diagnostic applications, a burgeoning pipeline of biopharmaceuticals, and increased government expenditure on healthcare. Prominent trends expected in the forecast period encompass the integration of technologies and ecosystems, the incorporation of genomic and precision medicine, continuous technological progress in production and engineering, the creation of biosimilars and next-generation antibodies, and breakthroughs in manufacturing platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27253&type=smp

What Are The Main Drivers Boosting The Chimeric Antibody Industry’s Expansion?

The escalating incidence of cancer is projected to stimulate the expansion of the chimeric antibody market moving forward. Cancer prevalence refers to the total number of individuals, both newly and previously diagnosed, who are alive with a history of cancer at a specific point in time. The increasing prevalence of cancer is attributed to lifestyle-related risks like poor nutrition, smoking, alcohol consumption, and exposure to environmental pollutants, which elevate the likelihood of developing various cancers. Chimeric antibodies enhance cancer treatment strategies by offering targeted therapies, proving effective against specific tumor cells. They reduce side effects by precisely attacking malignant cells, thereby improving patient outcomes and treatment efficiency. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia reached 160,570 in 2022, marking an increase of 3,789 cases from 156,781 in 2021. Thus, the rising prevalence of cancer is a significant force driving the growth of the chimeric antibody market.

What Are The Different Segment Classifications Within The Chimeric Antibody Market?

The chimeric antibody market covered in this report is segmented

1) By Type Of Antibody: Immunoglobulin G Chimeric Antibodies, Fragment Antigen-Binding Chimeric Antibodies, Single-Chain Variable Fragment Chimeric Antibodies

2) By Manufacturing Process: Recombinant Deoxyribonucleic Acid (DNA) Technology, Hybridoma Technology, Phage Display Technology, Transgenic Technology

3) By Mode Of Administration: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration

4) By Application: Cancer Therapy, Autoimmune Diseases, Infectious Diseases, Transplant Rejection

5) By End User: Pharmaceutical Companies, Research Institutes, Clinics And Hospitals, Diagnostic Laboratories

Subsegments:

1) By Immunoglobulin G Chimeric Antibodies: Full Length Immunoglobulin G (IgG), Engineered Immunoglobulin G 1 (IgG1), Engineered Immunoglobulin G4 (IgG4), Humanized Immunoglobulin G (IgG)

2) By Fragment Antigen-Binding Chimeric Antibodies, By Type: Bivalent Fragment Antigen-Binding (Fab) Fragments, Monovalent Fragment Antigen-Binding (Fab) Fragments, Conjugated Fragment Antigen-Binding (Fab) Fragments, Pegylated Fragment Antigen-Binding (Fab) Fragments

3) By Single-Chain Variable Fragment Chimeric Antibodies: Standard Single-Chain Fragment Variable, Tandem Single-Chain Fragment Variable, Bispecific Single-Chain Fragment Variable, Multivalent Single-Chain Fragment Variable

Which Key Trends Are Expected To Influence The Chimeric Antibody Market In The Coming Years?

Entities within the chimeric antibody market are primarily focusing on advanced therapeutic strategies, such as monoclonal antibodies, to enhance treatment results, elevate patient survival rates, and tackle serious medical ailments. Monoclonal antibodies are laboratory-developed proteins that replicate the immune system’s capability to fight harmful pathogens, encompassing viruses and agents causing inflammation. An example includes InflaRx N.V., a biopharmaceutical firm from Germany, which in June 2023, commercially introduced Gohibic (vilobelimab). This chimeric monoclonal antibody specifically targets C5a in the complement system, thereby blocking C5a-mediated immune reactions to reduce severe inflammation. It is employed for treating COVID-19 in hospitalized adults when administered within 48 hours of initiating invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). This innovative treatment represents a notable leap forward in addressing hyperinflammation in severe infections, offering a fresh therapeutic option for patients at high risk.

Which Leading Companies Dominate The Chimeric Antibody Market Share?

Major companies operating in the chimeric antibody market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., GenScript Biotech Corporation, Biocytogen Pharmaceuticals Co. Ltd., Creative Biolabs Inc., FairJourney Biologics S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chimeric-antibody-global-market-report

How Do Regional Market Performances Compare Within The Chimeric Antibody Industry?

North America was the largest region in the chimeric antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chimeric antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chimeric Antibody Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27253&type=smp

Browse Through More Reports Similar to the Global Chimeric Antibody Market 2025, By The Business Research Company

Semiconductor Intellectual Property Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/semiconductor-intellectual-property-global-market-report

Commercial Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/commercial-services-global-market-report

Legal Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/legal-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795